News

FDA Approval Brings Long Awaited Hope to Patients With Geographic Atrophy

by Jeff Todd, President + CEO at Prevent Blindness And just like that, the landscape for vision loss and blindness has shifted dramatically! For years, millions of people around the world who are living with an untreatable and potentially blinding condition, along with their care partners, have been waiting with hopeful anticipation for a treatment [Read More]

First Treatment For Geographic Atrophy Approved

FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Visual Impairment in Senior Adults   Apellis Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved SYFOVRE™ (pegcetacoplan injection) 15mg/0.1mL, the first and only treatment for geographic atrophy (GA) secondary to age-related [Read More]

New Study Finds Higher Prevalence of Age-Related Macular Degeneration (AMD) Cases than Previously Determined and a High Degree of County Variation

A new study “The Prevalence of Age-Related Macular Degeneration in the United States In 2019” published in JAMA Ophthalmology, found that in 2019, there were an estimated 19.83 million Americans were living with some form of age-related macular degeneration (AMD) in 2019. This is an increase of approximately more than 2.75 times previous estimates (which used a more [Read More]